Jo-Anne De la Mare

Prof. Jo-Anne De la Mare


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2014 in Recent Patents on Anti-Cancer Drug Discovery
Verified
Journal Article
Closed access
PDF file
JMJo-Anne De la Mare
Jo-Anne De la Mare
LCLara Contu
Lara Contu
MHMorgan C. Hunter
Morgan C. Hunter
BMBuhle Moyo
Buhle Moyo
JSJason N. Sterrenberg
Jason N. Sterrenberg
Adrienne Lesley EdkinsAdrienne Lesley Edkins
Adrienne Lesley Edkins
Due to the high heterogeneity of breast cancers, numerous recent patents describe improved methods of detection and classification which promise better patient prognosis and treatment. In particular, there has been a shift towards more effective genetic screening to identify specific mutations associated with breast tumours, which may lead to “personalised medicine” with improved outcomes. Two challenging areas of breast cancer research involve the development of treatments for the highly aggressive triple negative breast cancer subtype as well as the chemotherapy-resistant cancer stem cell subpopulation. In addition, despite numerous recent advances in breast cancer treatment in woman, male breast cancer remains poorly understood and there are limited therapies available which are developed specifically for men. This review serves to report on important developments in the treatment of breast malignancies patented in the past two years as well as to highlight the current gaps in the field of breast cancer therapeutics and areas which require further study.

1 April 2013 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
SSSuthananda Sunassee
Suthananda Sunassee
CVClinton Veale
Clinton Veale
NSNelusha Shunmoogam-Gounden
Nelusha Shunmoogam-Gounden
OOOmalaja Osoniyi
Omalaja Osoniyi
DHDenver T. Hendricks
Denver T. Hendricks
MDMichael Davies-Coleman
Michael Davies-Coleman

17 January 2012 in Investigational New Drugs
Verified
Journal Article
Closed access
PDF file
JMJo-Anne De la Mare
Jo-Anne De la Mare
JLJessica C. Lawson
Jessica C. Lawson
MCMaynard T. Chiwakata
Maynard T. Chiwakata
DBDenzil R. Beukes
Denzil R. Beukes
Adrienne Lesley EdkinsAdrienne Lesley Edkins
Adrienne Lesley Edkins
Gregory L. BlatchGregory L. Blatch
Gregory L. Blatch

1 May 2013 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
JMJo-Anne De la Mare
Jo-Anne De la Mare
JSJason N Sterrenberg
Jason N Sterrenberg
MSMugdha G Sukhthankar
Mugdha G Sukhthankar
MCMaynard T Chiwakata
Maynard T Chiwakata
DBDenzil Beukes
Denzil Beukes
Adrienne Lesley EdkinsAdrienne Lesley Edkins
Adrienne Lesley Edkins
Background: The cancer stem cell (CSC) theory proposes that tumours arise from and are sustained by a subpopulation of cells with both cancer and stem cell properties. One of the key hallmarks of CSCs is the ability to grow anchorage-independently under serum-free culture conditions resulting in the formation of tumourspheres. It has further been reported that these cells are resistant to traditional chemotherapeutic agents. Methods: In this study, the tumoursphere assay was validated in MCF-7 cells and used to screen novel marine algal compounds for potential anti-cancer stem cell (CSC) activity in vitro. Results: MCF-7 breast cancer cells were observed to generate tumourspheres or mammospheres after 3-5 days growth in anchorage-independent conditions and an apparent enrichment in potential CSCs was observed by an increase in the proportion of CD44high/CD24low marker-bearing cells and Oct4 expression compared to those in the bulk population grown in regular adherent conditions. Using this assay, a set of algal metabolites was screened for the ability to inhibit mammosphere development as a measure of potential anti-CSC activity. We report that the polyhalogenated monoterpene stereoisomers RU017 and RU018 isolated from the red alga Plocamium cornutum, both of which displayed no cytotoxicity against either adherent MCF-7 breast cancer or MCF-12A non-transformed breast epithelial cells, were able to prevent MCF-7 mammosphere formation in vitro. On the other hand, neither the brown algal carotenoid fucoxanthin nor the chemotherapeutic paclitaxel, both of which were toxic to adherent MCF-7 and MCF-12A cells, were able to inhibit mammosphere formation. In fact, pre-treatment with paclitaxel appeared to enhance mammosphere formation and development, a finding which is consistent with the reported resistance of CSCs to traditional chemotherapeutic agents. Conclusion: Due to the proposed clinical significance of CSC in terms of tumour initiation and metastasis, the identification of agents able to inhibit this subpopulation has clinical significance.

16 March 2017 in BMC Cancer
Verified
Journal Article
Open access
PDF file
JMJo-Anne De la Mare
Jo-Anne De la Mare
TJTamarin Jurgens
Tamarin Jurgens
Adrienne Lesley EdkinsAdrienne Lesley Edkins
Adrienne Lesley Edkins
Tumour metastasis remains the major cause of death in cancer patients and, to date, the mechanism and signalling pathways governing this process are not completely understood. The TGF-β pathway is the most commonly mutated pathway in cancer, however its role in cancer progression is controversial as it can function as both a promoter and a suppressor of metastasis. Although previous studies have suggested a role for the molecular chaperone Hsp90 in regulating the TGF-β pathway, the level at which this occurs as well as the consequences in terms of colon cancer metastasis are unknown. The paired SW480 and SW620 colon cancer cell lines, derived from a primary tumour and its lymph node metastasis, respectively, were used as an in vitro model to study key cellular processes required for metastasis. The status of the TGF-β pathway was examined in these cells using ELISA, flow cytometry, western blot analysis and confocal microscopy. Furthermore, the effect of addition or inhibition of the TGF-β pathway and Hsp90 on adhesion, migration and anchorage-independent growth, was determined in the cell lines. When comparing the canonical TGF-β1 pathway in the genetically paired cell lines our data suggests that this pathway may be constitutively active in the SW620 metastasis-derived cell line and not the SW480 primary tumour-derived line. In addition, we report that, when present in combination, TGF-β1 and Hsp90β stimulate anchorage-independent growth, reduce adhesion and stimulate migration. This effect is potentiated by inhibition of the TGF-β1 receptor and occurs via an alternate TGF-β1 pathway, mediated by αvβ6 integrin. Interestingly, in the SW620 cells, activation of this alternate TGF-β1 signalling machinery does not appear to require inhibition of the canonical TGF-β1 receptor, which would allow them to respond more effectively to the pro-metastasis stimulus of a combination of Hsp90β and TGF-β1 and this could account for the increased migratory capacity of these cells. In this study we report an apparent synergy between TGF-β1 and Hsp90β in stimulating migratory behaviour of colon cancer cells when signalling occurs via αvβ6 integrin as opposed to the canonical TGF-β1 pathway.

2 March 2021 in Molecules
Verified
Journal Article
Open access
PDF file
MMMziyanda Mbaba
Mziyanda Mbaba
LDLaura M. K. Dingle
Laura M. K. Dingle
AZAyanda Zulu
Ayanda Zulu
DLDustin Laming
Dustin Laming
TSTarryn Swart
Tarryn Swart
SKSetshaba David Khanye
Setshaba David Khanye
A tailored series of coumarin-based ferrocenyl 1,3-oxazine hybrid compounds was synthesized and investigated for potential antiparasitic activity, drawing inspiration from the established biological efficacy of the constituent chemical motifs. The structural identity of the synthesized compounds was confirmed by common spectroscopic techniques: NMR, HRMS and IR. Biological evaluation studies reveal that the compounds exhibit higher in vitro antiparasitic potency against the chemosensitive malarial strain (3D7 P. falciparum) over the investigated trypanosomiasis causal agent (T. b. brucei 427) with mostly single digit micromolar IC50 values. When read in tandem with the biological performance of previously reported structurally similar non-coumarin, phenyl derivatives (i.e., ferrocenyl 1,3-benzoxazines and α-aminocresols), structure-activity relationship analyses suggest that the presence of the coumarin nucleus is tolerated for biological activity though this may lead to reduced efficacy. Preliminary mechanistic studies with the most promising compound (11b) support hemozoin inhibition and DNA interaction as likely mechanistic modalities by which this class of compounds may act to produce plasmocidal and antitrypanosomal effects.